
|Videos|June 26, 2020
Clinical Ramifications of Pneumococcal Vaccine Development
Author(s)Contagion® Editorial Staff
Dr. Luwy Musey, executive director in biologics, Merck Research Laboratories, discusses what clinicians need to know about the latest PCVs.
Advertisement
Segment Description: Dr. Luwy Musey, executive director in biologics, vaccine clinical research, Merck Research Laboratories, discusses what clinicians need to know about the latest PCVs.
Part 1: Developments in Pneumococcal Conjugate Vaccines
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Advertisement
Advertisement
Trending on Contagion Live
1
Phase 3 Trial Confirms Superior Efficacy of Oral Pritelivir for Refractory HSV in Immunocompromised Patients
2
Developing the Next Generation of Rifamycins for Non-TB Mycobacteria in a Post-Antibiotic Era
3
Higher Acceptability of 1 Injectable in First Head-to-Head Comparison of Long-Acting PrEP
4